Author

J. D. Brenton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 9 Cell Biology· 1 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 10 Approach:experimental assay· 7 Assay:whole-genome sequencing· 6 Approach:statistical model· 5 Research Focus:differential expression· 4 Research Focus:drug response / drug discovery· 4 Assay:bulk RNA-seq· 3 Organism:mouse· 3

Frequent Co-Authors

D.-L. Couturier· 5 shared M. Vias· 5 shared C. M. Sauer· 4 shared K. Hosking· 4 shared M. Jimenez-Linan· 4 shared A. M. Piskorz· 3 shared D. Sanders· 3 shared F. Correia Martins· 3 shared

Activity by Year

2017-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

D.-L. Couturier

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

Heme oxygenase-1 expressing omental macrophages as a therapeutic target in ovarian high grade serous carcinoma

S. Spear, O. Le Saux, H. B. Mirza, K. Tyson, J. Bickel, F. Grundland Freile, A. P. Siskos, C. Balcells, J. B. Walton, C. Woodman, D. P. Ennis, N. Iyer, C. Aguirre Hernandez, Y. Xu, P. Spiliopoulou, , I. A. McNeish

This study identifies HMOX1-expressing omental macrophages as a therapeutic target and biomarker for poor prognosis ovarian high-grade serous carcinoma.

bioRxiv · Jul 18, 2023 · PreprintCancer Biology

Rare germline genetic variation in PAX8 transcription factor binding sites and susceptibility to epithelial ovarian cancer

S. A. M. Ezquina, M. Jones, E. Dicks, A. de Vries, P.-C. Peng, R. I. Corona, K. Lawrenson, J. P. Tyrer, D. Hazelett, J. D. Brenton, A. C. Antoniou, S. A. Gayther, P. D. P. Pharoah

This study investigates rare germline variation in PAX8 binding sites for ovarian cancer risk using burden testing but finds no significant association.

medRxiv · Mar 22, 2023 · PreprintGenetic & Genomic Medicine

Predicting response to cytotoxic chemotherapy

J. Thompson, L. Madrid, B. Hernando, C. Sauer, M. Vias, M. Escobar-Rey, W.-K. Leung, J. Huckstep, M. Sekowska, K. Hosking, M. Jimenez-Linan, M. Reinius, H. Dobson, D. De Silva, A. Fernandez-Sanroman, , G. Macintyre

This study develops three precision biomarkers based on chromosomal instability signatures to predict response to different chemotherapies, showing improved progression-free survival in clinical trials.

bioRxiv · Jan 28, 2023Cancer Biology

Molecular landscape and functional characterization of centrosome amplification in ovarian cancer

C. M. Sauer, J. A. Hall, D.-L. Couturier, T. Bradley, A. M. Piskorz, J. Griffiths, A. Sawle, M. D. Eldridge, P. Smith, K. Hosking, M. A. Reinius, L. Morrill Gavarro, A.-M. Mes-Masson, D. Ennis, D. Millan, , J. D. Brenton

This study identifies centrosome amplification as a common and heterogeneous feature in HGSOC, linked to CIN and treatment resistance.

bioRxiv · Sep 13, 2022Cancer Biology

High-grade serous ovarian carcinoma organoids as models of chromosomal instability

M. Vias, L. Morrill Gavarro, C. M. Sauer, D. Sanders, A. M. Piskorz, D.-L. Couturier, S. Ballereau, B. Hernando, J. Hall, F. Correia-Martins, F. Markowetz, G. Macintyre, J. D. Brenton

This study develops HGSOC patient-derived organoids to model chromosomal instability and its mutational processes, showing they represent different causes of instability and can be used for drug sensitivity testing.

bioRxiv · Sep 1, 2022Cancer Biology

LGR5 targeting molecules as therapeutic agents for multiple cancer types

H.-C. Chen, N. Mueller, K. Stott, E. Rivers, C. Kapeni, C. M. Sauer, F. Beke, S. Walsh, N. Ashman, L. M. O'Brien, A. R. Fard, A. Godsinia, F. Joud, O. Giger, I. Zlobec, , M. de la Roche

This study develops LGR5-targeting antibodies and therapeutics that effectively kill CRC, HCC, and pre-B ALL cancer cells while sparing normal tissues.

bioRxiv · Sep 1, 2022 · PreprintCell Biology

Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models

C. M. Sauer, K. Heider, J. Belic, S. E. Boyle, J. A. Hall, D.-L. Couturier, A. An, A. Vijayaraghavan, M. A. Reinius, K. Hosking, M. Vias, N. Rosenfeld, J. D. Brenton

This study develops a method to monitor ctDNA in PDX mice using dried blood spots, enabling longitudinal tracking of disease burden and treatment response.

bioRxiv · Jan 15, 2022Cancer Biology

Somatic chromosomal number alterations affecting driver genes inform in-vitro and clinical drug response in high-grade serous ovarian cancer

F. Correia Martins, D.-L. Couturier, I. Santiago, C. Sauer, M. Vias, M. Angelova, D. Sanders, A. Piskorz, J. Hall, K. Hosking, A. Amirthanayagam, S. Cosulich, L. Carnevalli, B. Davies, T. B. K. Watkins, , J. D. Brenton

This study shows that somatic copy number alterations in driver genes correlate with drug response in HGSOC spheroid models and clinical settings.

bioRxiv · Oct 4, 2020 · PreprintCancer Biology

Detection of ctDNA from dried blood spots after DNA size selection

K. Heider, J. C. Wan, J. Hall, S. Boyle, I. Hudecova, D. Gale, W. N. Cooper, P. G. Corrie, J. D. Brenton, C. G. Smith, N. Rosenfeld

This paper develops a protocol to detect ctDNA from dried blood spots using low-depth WGS and fragment size selection, showing its feasibility in human and mouse models.

bioRxiv · Sep 5, 2019Cancer Biology

Unraveling Tumor-Immune Heterogeneity in Advanced Ovarian Cancer Uncovers Immunogenic Effect of Chemotherapy

A. Jimenez-Sanchez, P. Cybulska, K. Lavigne, T. Walther, I. Nikolovski, Y. Mazaheri, B. Weigelt, D. S. Chi, K. J. Park, T. Hollmann, D.-L. Couturier, A. Vargas, J. D. Brenton, E. Sala, A. Snyder, M. L. Miller

This study analyzes tumor-immune heterogeneity in ovarian cancer before and after chemotherapy, finding that chemotherapy increases cytotoxic immune activation in site-matched samples.

bioRxiv · Oct 17, 2018Cancer Biology

Copy-number signatures and mutational processes in ovarian carcinoma

G. Macintyre, T. Goranova, D. De Silva, D. Ennis, A. M. Piskorz, M. Eldridge, D. Sie, L.-A. Lewsley, A. Hanif, C. Wilson, S. Dowson, R. M. Glasspool, M. Lockley, E. Brockbank, A. Montes, , J. D. Brenton

This study identifies copy-number signatures in ovarian cancer and links them to mutational processes, showing that most cases involve multiple processes, suggesting therapeutic challenges.

bioRxiv · Sep 4, 2017Cancer Biology